Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp has demonstrated notable financial performance, particularly in its plasma segment, which experienced a remarkable organic growth rate of 20.2%, indicating strong demand and an increase in market share. The adjusted operating margin in the plasma business also improved by 60 basis points to 36.2%, reflecting effective cost management and enhanced profitability across all segments. Additionally, the company's forecast for free cash flow has been revised upward to $200-220 million, indicating robust cash generation capabilities and a favorable outlook for financial stability.

Haemonetics Corp reported a significant decline of 19.6% in revenue, heavily impacted by divestiture activities, which indicates underlying challenges in revenue generation despite a modest 2.8% organic growth. Additionally, the company's FY/26 guidance projects a potential revenue decline of 1% to 4%, which raises concerns regarding its ability to maintain growth momentum in the competitive healthcare market. The substantial organic declines in key segments, especially the 11.6% drop in interventional technologies and the stagnation in vascular closure revenue, suggest that Haemonetics may struggle to capitalize on its growth potential in the forthcoming fiscal periods.